GlassScriptPhysician profile
Eugene Daniel Festa
NPI 1629395629
$12,949.79
in general payments reported to CMS, 2019-2025
46 companies · $3,411 in 2025
The $3,411 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.45 · 2020: $1,240 · 2021: $1,432 · 2022: $1,361 · 2023: $2,348 · 2024: $3,095 · 2025: $3,411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,805 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,804.80 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,892.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,148.15 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Gilead Sciences, INC. | $1,586.35 | 2020-2025 | Descovy, Biktarvy |
| Novo Nordisk INC | $815.38 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Antares Pharma, INC. | $635.30 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Indivior INC. | $569.68 | 2020-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.82 | 2020-2025 | Xifaxan, Trulance, Relistor |
| Braeburn INC. | $549.76 | 2023-2025 | Brixadi |
| Pfizer INC. | $522.88 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.40 | 2024-2025 | Caplyta |
| Glaxosmithkline, LLC. | $243.99 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Viiv Healthcare Company | $242.51 | 2022-2025 | Apretude |
| Supernus Pharmaceuticals, INC. | $181.19 | 2022-2023 | Xyosted, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $174.63 | 2019-2024 | Trintellix |
| Axsome Therapeutics, INC. | $141.76 | 2023-2025 | Auvelity |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Festa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.